



Medicaid and Health Wave
900 SW Jackson Street
Rm. 900-N
Topeka, KS 66612
Phone: 785-296-3981
Fax: 785-296-4813
www.khpa.ks.gov

Drug Utilization Review Board Meeting
Meeting Agenda, Open Session
July 8, 2009, 10:00a.m.

Meeting Location:

EDS, an HP company ~ Capital and Cedar Crest Rooms
6700 SW Topeka Blvd, Bldg. 283 J, Topeka, Kansas 66619

Committee Members:

Michael Burke, M.D, Ph.D.	Dennis Grauer, Ph.D.
John Kollhoff, Pharm.D.	Judy McDaniel Dowd, PA-C
Brenda Schewe, M.D.	Daniel Sutherland, R.Ph.
Roger Unruh, D.O	Kevin Waite, Pharm.D.

KHPA Staff:

LeAnn Bell, Pharm.D.	Aimee Grubb, Recorder
Shelly Liby	Margaret Smith, M.D., M.P.H., M.H.S.A.

EDS Staff:

Karen Kluczykowski, R.Ph.	Debra Quintanilla, R.N.
Lisa Todd, R.Ph.	

- I. Call to Order
- II. Announcements
- III. Old Business
 - A. Review and Approval of May 13, 2009 Meeting Minutes
 - B. Aromatase Inhibitors - Arimidex[®] (anastrozole), Femara[®] (letrozole), Aromasin[®] (exemestane)
 - i. New PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

IV. New Business

- A. Health Information Designs (HID)
 - i. Fiscal Year 2010 Intervention Selection
 - ii. Academic detailing

- B. Cinryze[®] (C1 inhibitor, human injection)
 - i. New PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- C. Promacta[®] (eltrombopag)
 - i. New PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- D. Xyrem[®] (sodium oxybate)
 - i. New PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- E. Simponi[®] (golimumab)
 - i. New PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- F. Lupron[®] (leuprolide acetate)
 - i. Diagnosis Restrictions
 - ii. *Public Comment
 - iii. Board Discussion/Action

- G. Synagis[®] (palivizumab)
 - i. Revised PA Criteria
 - ii. *Public Comment
 - iii. Board Discussion/Action

- H. Adjunct Antiepileptics - Lyrica[®] (pregabalin), Neurontin[®] (gabapentin), Gabitril[®] (tiagabine), Zonegran[®] (zonisamide), Keppra[®] & Keppra XR[®] (levetiracetam), Vimpat[®] (lacosamide), Banzel[®] (rufinamide)
 - i. Dose Restrictions
 - ii. *Public Comment
 - iii. Board Discussion/Action

- I. Short Acting Opioids - morphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, oxycodone, oxymorphone
 - i. Dose Restrictions
 - ii. *Public Comment
 - iii. Board Discussion/Action

- J. PDL drug class criteria review - *Public Comment and Board Discussion/Action for Each Class
 - i. Proton pump inhibitors
 - ii. Antiemetics
 - iii. Urinary incontinence drugs
 - iv. Fibric acid derivatives
 - v. Inhaled corticosteroids
 - vi. NSAIDS
 - vii. Adjunct Antiepileptics
 - viii. Xanthine oxidase inhibitors

V. Adjourn

*Public Comment is limited to five minutes per product; additional time will be allowed at the Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

**Lunch for DUR Board Members after meeting adjourned
NEXT MEETING: October 21, 2009**